TrialJournal of cancer research and clinical oncology2023

Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.

Chao Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.